Results 91 to 100 of about 63,206 (209)

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries

Journal of Virus Eradication, 2015
Background: In 2013, an estimated 686,000 people died from hepatitis B virus (HBV) infection worldwide. Mass treatment programmes for hepatitis B will require very low drug costs.
Andrew Hill, Dzintars Gotham, Graham Cooke, Sanjay Bhagani, Isabelle Andrieux-Meyer, Jennifer Cohn, Joseph Fortunak   +6 more
doaj   +1 more source

Pre‐exposure prophylaxis use in blood donors in England

Vox Sanguinis, EarlyView.
Abstract Background and Objectives The For the Assessment of Individualized Risk (FAIR) framework, introduced by NHS Blood and Transplant (NHSBT) in 2021, aims to reduce stigma and improve equity in blood donor selection, particularly for gay, bisexual and other men who have sex with men (GBMSM).
Jaid Debrah, Claire Reynolds, Victoria Maddox, Shannah Secret, Hatice Baklan, Alieu Amara, Laura Else, Peter Simmonds, Susan R. Brailsford, Saye Khoo, Heli Harvala   +10 more
wiley   +1 more source

The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi [PDF]

, 2009
The incremental cost effectiveness of an integrated care package (i.e., medical care including antiretroviral therapy (ART) and other services such as psychological and social support) for people living with HIV/AIDS was calculated in a not-for-profit ...
Basenya, O, de Borman, N, Greindl, I, Meyer-Rath, G, Renaud, A   +4 more
core   +3 more sources

Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV

International Journal of Cancer, Volume 158, Issue 9, Page 2298-2308, 1 May 2026.
What's new? This large nation‐wide cohort study provides a comprehensive 20‐year analysis of cancer trends among people living with HIV in France, highlighting persistent excess risks for virus‐related cancers despite effective antiretroviral therapy and immune restoration.
Sophie Grabar, Paula Lakrout, Valérie Potard, Aurélien Belot, Jacques Cadranel, Christine Jacomet, Christine Katlama, Esaïe Marshall, Olivier Lambotte, Romain Palich, Sylvie Ronot‐Bregigeon, Jean‐Philippe Spano, Anne‐Marie Bouvier, Alain Makinson, Dominique Costagliola   +14 more
wiley   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof‐of‐Concept Study

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
Neglected tropical diseases (NTDs) remain a major global health challenge, particularly in low‐ and middle‐income countries. Kinetoplastid parasites causing Chagas disease, leishmaniasis, and African trypanosomiasis rely on host purine salvage pathways, making nucleoside analogues attractive therapeutic candidates.
Silvester Lowe, Vishal Satikuvar, Tanjia M. Syeda, Monica Cal, Pascal Mäser, Marcel Kaiser, Hachemi Kadri   +6 more
wiley   +1 more source

Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta‐Analysis

JGH Open
Background Hepatitis B virus (HBV) infection causes liver disease, including hepatocellular carcinoma. Controlling viral activity is crucial to reducing complications.
Muhammad Shahzil, Ammad Javaid Chaudhary, Talha Kashif, Ali Akram Qureshi, Anza Muhammad, Faiza Khan, Muhammad Saad Faisal, Muhammad Ali Khaqan, Hassam Ali, Yara Dababneh, Dilip Moonka   +10 more
doaj   +1 more source

Ethical Challenges of Preexposure Prophylaxis for HIV [PDF]

, 2012
On July 16, 2012, emtricitabine/tenofovir (Truvada) became the first drug approved by the US Food and Drug Administration for preexposure prophylaxis (PrEP) of human immunodeficiency virus (HIV) for adults at high risk.
Gostin, Lawrence O., Jay, Jonathan S.
core   +3 more sources

Translation of a physiologically‐based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post‐partum women

British Journal of Clinical Pharmacology, Volume 92, Issue 4, Page 1109-1116, April 2026.
Aims To translate a PBPK model developed for the direct oral anticoagulant, dabigatran etexilate, the prodrug of dabigatran, based on data obtained from healthy men to healthy non‐pregnant, pregnant and post‐partum women. To evaluate safety and efficacy of dabigatran etexilate in post‐partum women using simulations and design a future clinical study to
Kayode Ogungbenro, Lorna Aucott, Farhad Kamali, Paul Ayuk   +3 more
wiley   +1 more source

New Perspectives on Treatment of Hepatitis B Before and After Liver Transplantation [PDF]

, 2016
open5noThe hepatitis B virus (HBV) infects more than 260 million people globally, with increasing incidence, especially in developing countries.
Bortoluzzi, Ilaria, Burra, Patrizia, Ferrarese, Alberto, Russo, Francesco Paolo, Zanetto, Alberto   +4 more
core   +1 more source